IPIX (Innovation Pharmaceuticals) Debt-to-Asset : 0.04 (As of Sep. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Innovation Pharmaceuticals Debt-to-Asset?

Innovation Pharmaceuticals IPIX Debt-to-Asset is 0.04 as of Sep. 2023.

Innovation Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.24 Mil. Innovation Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.00 Mil. Innovation Pharmaceuticals's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Sep. 2023 was $6.67 Mil. Innovation Pharmaceuticals's debt to asset for the quarter that ended in Sep. 2023 was 0.04.

Innovation Pharmaceuticals  (OTCPK:IPIX) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Innovation Pharmaceuticals Debt-to-Asset Related Terms

Innovation Pharmaceuticals Debt-to-Asset Historical Data

* Premium members only.

The historical data trend for Innovation Pharmaceuticals's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Innovation Pharmaceuticals Debt-to-Asset Chart

Innovation Pharmaceuticals Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.48 0.27 0.13 0.05 0.04

Innovation Pharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.05 0.05 0.04 0.04 0.04

IPIX vs AXIM, RNAZ, APTX: Debt-to-Asset Comparison

For the Biotechnology subindustry, Innovation Pharmaceuticals's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Innovation Pharmaceuticals Debt-to-Asset vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innovation Pharmaceuticals's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Innovation Pharmaceuticals's Debt-to-Asset falls into.


Innovation Pharmaceuticals Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Innovation Pharmaceuticals's Debt-to-Asset for the fiscal year that ended in Jun. 2023 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0.268 + 0) / 7.517
=0.04

Innovation Pharmaceuticals's Debt-to-Asset for the quarter that ended in Sep. 2023 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0.238 + 0) / 6.667
=0.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Asset →
What does a Debt-to-Asset of 0.04 mean?
Innovation Pharmaceuticals (IPIX) has a Debt-to-Asset of 0.04 as of Sep. 2023. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Innovation Pharmaceuticals and its competitors.
Is Innovation Pharmaceuticals' Debt-to-Asset too high?
Innovation Pharmaceuticals' current Debt-to-Asset is 0.04.
How does Innovation Pharmaceuticals' Debt-to-Asset compare to AXIM and RNAZ?
Innovation Pharmaceuticals' Debt-to-Asset of 0.04 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Asset for a Biotechnology company?
A good Debt-to-Asset depends on the Biotechnology industry context. However, Debt-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Asset mean?
A high Debt-to-Asset can signal that a stock is expensive relative to its fundamentals. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Innovation Pharmaceuticals and its competitors. Innovation Pharmaceuticals's current Debt-to-Asset is 0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Innovation Pharmaceuticals stock overvalued right now?
Innovation Pharmaceuticals (IPIX) has a current Debt-to-Asset of 0.04. The current Debt-to-Asset is 0.04. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Asset calculated?
Debt-to-Asset is calculated from a company's financial statements. For Innovation Pharmaceuticals (IPIX), the current Debt-to-Asset is 0.04 as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Innovation Pharmaceuticals Business Description

Address 301 Edgewater Place, Suite 100, Wakefield, MA, USA, 01880
Innovation Pharmaceuticals Inc is a clinical-stage pharmaceutical company in the United States. It is engaged in developing therapies with oncology, dermatology, and antimicrobial applications. Its clinical trials focus on evaluating its drug candidates, including Kevetrin for the treatment of cancers; Brilacidin, a potential therapeutic for the treatment of the novel coronavirus. The company focuses on developing small molecule therapies to treat diseases in the areas of cancer, antibiotics, and inflammatory disease.